Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 241
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 511-522
Open Access | Times Cited: 237
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 47
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 45
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Lianzhou Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 40
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes
Lindsey Wang, Nathan A. Berger, David C. Kaelber, et al.
Gastroenterology (2024) Vol. 167, Iss. 4, pp. 689-703
Open Access | Times Cited: 32
Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
Brent Hiramoto, Thomas R. McCarty, Nayna A. Lodhia, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 6, pp. 1126-1140
Closed Access | Times Cited: 25
Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective
Luis Antonio Díaz, Daniel König, Sabine Weber, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 2
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 35
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 33
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 33
Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon
Christopher D. Byrne, Giovanni Targher, Herbert Tilg
Gut (2024), pp. gutjnl-330596
Open Access | Times Cited: 13
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 10
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
David R. Riley, Theresa Hydes, Gema Hernadez, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2538-2550
Open Access | Times Cited: 9
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, et al.
Gut (2024), pp. gutjnl-332687
Closed Access | Times Cited: 9
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Lixuan Fang, Jine Li, Haixia Zeng, et al.
Primary care diabetes (2024) Vol. 18, Iss. 3, pp. 268-276
Closed Access | Times Cited: 7
Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
Kai Zhu, Rohan Kakkar, Daljeet Chahal, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 37, pp. 5327-5338
Open Access | Times Cited: 17
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Branka Filipović, Marija Marjanovic-Haljilji, Dragana Mijač, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 9132-9148
Open Access | Times Cited: 16
Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives
Atsushi Tanaka, Koichi Node
Hypertension Research (2024) Vol. 47, Iss. 12, pp. 3338-3344
Closed Access | Times Cited: 6
Flavonoids for gastrointestinal tract local and associated systemic effects: A review of clinical trials and future perspectives
Xiaopeng Li, Enjun Xie, Shumin Sun, et al.
Journal of Advanced Research (2025)
Open Access
Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
Jinliang Liang, Huanyi Liu, Guo Lv, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Gut (2025), pp. gutjnl-334591
Closed Access
Metabolic hormones are integral regulators of female reproductive health and function
Faria Athar, M. Karmani, Nicole M. Templeman
Bioscience Reports (2023) Vol. 44, Iss. 1
Open Access | Times Cited: 15
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study
Win Min Han, Tanakorn Apornpong, Hay Mar Su Lwin, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 12, pp. 1687-1695
Closed Access | Times Cited: 14
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Jean‐Baptiste Bonnet, Sarah Tournayre, Jean Anitcheou, et al.
Obesity (2023) Vol. 32, Iss. 1, pp. 50-58
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top